ONCY
Oncolytics Biotech, Inc.

7,314
Mkt Cap
$110.39M
Volume
289,450.00
52W High
$1.51
52W Low
$0.3258
PE Ratio
-3.70
ONCY Fundamentals
Price
$1.03
Prev Close
$1.04
Open
$1.05
50D MA
$1.21
Beta
0.86
Avg. Volume
881,809.09
EPS (Annual)
-$0.3026
P/B
1,300.00
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
FY2025 EPS Estimate for Oncolytics Biotech Lifted by Analyst
Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Investment analysts at HC Wainwright lifted their FY2025 EPS estimates for Oncolytics Biotech in a research note issued on Monday, November 17th...
MarketBeat·5h ago
News Placeholder
More News
News Placeholder
All You Need to Know About Oncolytics Biotech (ONCY) Rating Upgrade to Buy
Oncolytics Biotech (ONCY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·24h ago
News Placeholder
Oncolytics Biotech Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer
Oncolytics Biotech Inc. (Nasdaq: ONCY) (Oncolytics or the Company), a clinical-stage immunotherapy company developing pelareorep, today announced alignment with the U.S. Food and Drug Administration...
Business Wire·1d ago
News Placeholder
Oncolytics Biotech (NASDAQ:ONCY) Downgraded to "Sell" Rating by Wall Street Zen
Wall Street Zen cut shares of Oncolytics Biotech from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·4d ago
News Placeholder
Oncolytics Biotech (NASDAQ:ONCY) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS
Oncolytics Biotech (NASDAQ:ONCY - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts...
MarketBeat·6d ago
News Placeholder
Oncolytics Biotech Inc. (NASDAQ:ONCY) Given Average Recommendation of "Moderate Buy" by Analysts
Oncolytics Biotech Inc. (NASDAQ:ONCY - Get Free Report) has received an average recommendation of "Moderate Buy" from the seven ratings firms that are currently covering the company, MarketBeat...
MarketBeat·13d ago
News Placeholder
Oncolytics Biotech Establishes Gastrointestinal Tumor Scientific Advisory Board to Advance Pelareorep as a Platform Immunotherapy
Oncolytics Biotech Inc. (Nasdaq: ONCY) (Oncolytics or the Company), a clinical-stage immunotherapy company developing pelareorep, today announced the formation of its Gastrointestinal (GI) Tumor...
Business Wire·16d ago
News Placeholder
Oncolytics Biotech Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care
Oncolytics Biotech Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care Oncolytics Biotech Reports Updated Anal Cancer Data Showing Objective...
PR Newswire·23d ago
News Placeholder
Oncolytics Biotech to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
Oncolytics Biotech to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights Oncolytics Biotech to Host Conference Call to Discuss Fourth...
PR Newswire·9mo ago
News Placeholder
Investors Eye Biotech Sector as Cancer Therapy Market Surges
Investors Eye Biotech Sector as Cancer Therapy Market Surges Investors Eye Biotech Sector as Cancer Therapy Market Surges PR Newswire VANCOUVER, BC, Feb. 19, 2025 USA News Group News CommentaryIssued...
PR Newswire·9mo ago

Latest ONCY News

View

Advertisement|Remove ads.

Advertisement|Remove ads.